- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00062127
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
A Phase I Pharmacokinetic Interaction Study of Irinotecan (NSC616348) and Thalidomide (NSC66847) in Patients With Advanced Solid Tumors
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. Determine whether thalidomide alters the pharmacokinetics of irinotecan in patients with advanced solid tumors.
II. Determine whether irinotecan alters the pharmacokinetics of thalidomide in these patients.
III. Determine the toxicity of this regimen in these patients. IV. Determine the observed antitumor response in patients treated with this regimen.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28.
Arm II: Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7.
All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637-1470
- University of Chicago Comprehensive Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Histologically confirmed malignant solid tumor
- Metastatic or unresectable
- Standard curative or palliative therapy is no longer effective or does not exist
- Measurable or assessable disease
No uncontrolled brain metastases
Patients with brain metastases are eligible provided the following are true:
- Stable neurologic status
- At least 4 weeks since prior steroids or anticonvulsants
- No neurologic dysfunction that would confound evaluation
- Performance status - Karnofsky 70-100%
- More than 12 weeks
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin normal
- AST and ALT no greater than 2.5 times upper limit of normal
- Creatinine normal
- Creatinine clearance at least 60 mL/min
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No history of inflammatory bowel disease requiring therapy
- No chronic diarrhea syndromes
- No paralytic ileus
- Not pregnant or nursing
- Negative pregnancy test
- Fertile female patients must use 2 forms of effective contraception, including 1 highly effective method, for at least 4 weeks before, during, and for 4 weeks after study participation
- Male patients must use effective barrier contraception during and for 4 weeks after study participation
- No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
- No uncontrolled seizure disorder
- No other concurrent uncontrolled illness that would preclude study participation
- No psychiatric illness or social situation that would preclude study compliance
- No ongoing or active infection
- No significant traumatic injury within the past 28 days
- No serious, nonhealing wounds or ulcers
- No bone fractures
- No preexisting peripheral neuropathy grade 2 or greater
- At least 4 weeks since prior biologic therapy
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- See Disease Characteristics
- At least 4 weeks since prior radiotherapy
- More than 28 days since prior major surgical procedure or open biopsy
- At least 4 weeks since prior investigational therapy
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational or commercial agents or therapies for the malignancy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Arm I (irinotecan hydrochloride and thalidomide)
Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28.
All patients undergo disease re-evaluation at 6 weeks.
Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Korrelativa studier
Andra namn:
Givet IV
Andra namn:
Ges oralt
Andra namn:
|
Experimentell: Arm II (irinotecan hydrochloride and thalidomide)
Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks.
Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Korrelativa studier
Andra namn:
Givet IV
Andra namn:
Ges oralt
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Effect of thalidomide on irinotecan hydrochloride pharmacokinetics
Tidsram: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours
|
Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours
|
|
Effect of irinotecan hydrochloride on thalidomide pharmacokinetics
Tidsram: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 and 168 hours
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 and 168 hours
|
|
Grade 3 or greater toxicities assessed using NCI CTC version 2.0
Tidsram: Up to 3 years
|
Will be summarized and analyzed using descriptive statistics.
Exact 90% confidence intervals using the binomial distribution will be derived.
|
Up to 3 years
|
Response assessed using RECIST criteria
Tidsram: Up to 3 years
|
Will be summarized and analyzed using descriptive statistics.
Exact 90% confidence intervals using the binomial distribution will be derived.
|
Up to 3 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Mark Ratain, University of Chicago Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Enzyminhibitorer
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Topoisomerasinhibitorer
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Antibakteriella medel
- Leprostatiska medel
- Topoisomeras I-hämmare
- Talidomid
- Irinotekan
Andra studie-ID-nummer
- NCI-2012-02537
- U01CA069852 (U.S.S. NIH-anslag/kontrakt)
- 12044B
- CDR0000304517 (Registeridentifierare: PDQ (Physician Data Query))
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på farmakologisk studie
-
Tampere University HospitalAvslutad
-
Radicle ScienceAktiv, inte rekryterandeKognitiv funktionFörenta staterna
-
University of MichiganAvslutad
-
Scion NeuroStimAnmälan via inbjudanParkinsons sjukdom | Parkinsons sjukdom och ParkinsonismFörenta staterna
-
Apple Inc.Stanford UniversityAvslutadFörmaksflimmer | Arytmier, hjärt | FörmaksfladderFörenta staterna
-
Boston Scientific CorporationAvslutadVentrikulär takykardiAustralien
-
Radicle ScienceRekryteringSmärta | Neuropatisk smärta | Nociceptiv smärtaFörenta staterna
-
Brock UniversityDairy Farmers of CanadaAvslutadFetma | Övervikt | BarnKanada
-
Radicle ScienceAktiv, inte rekryterandePåfrestning | ÅngestFörenta staterna